OTCMKTS:MEOBF - Mesoblast Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $1.03 0.00 (0.00 %) (As of 07/18/2018 06:00 AM ET)Previous Close$1.03Today's Range$1.03 - $1.0352-Week Range$0.95 - $1.55VolumeN/AAverage Volume2,960 shsMarket Capitalization$634.14 millionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia. Receive MEOBF News and Ratings via Email Sign-up to receive the latest news and ratings for MEOBF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolOTCMKTS:MEOBF CUSIPN/A Webwww.mesoblast.com PhoneN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares470,600,000Market Cap$634.14 Mesoblast (OTCMKTS:MEOBF) Frequently Asked Questions What is Mesoblast's stock symbol? Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF." What is the consensus analysts' recommendation for Mesoblast? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of Mesoblast's key competitors? Some companies that are related to Mesoblast include MorphoSys (MOR), Almirall (LBTSF), Sosei Group (SOLTF), Sirtex Medical (SRX), Genus (GNS), Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB) and BioTime (BTX). Who are Mesoblast's key executives? Mesoblast's management team includes the folowing people: Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 61)Mr. Josh Muntner, Chief Financial Officer (Age 49)Dr. Suzanne Lipe BSc (Hons), Ph.D., LLB, VP of Operations (Age 68)Mr. Jonathan Richard Symonds, Head of Corp. Fin. & Strategy (Age 59)Mr. Peter Howard BSc, LLB (Hons), Gen. Counsel & Corp. Exec. (Age 50) Has Mesoblast been receiving favorable news coverage? News stories about MEOBF stock have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mesoblast earned a media sentiment score of 0.17 on Accern's scale. They also assigned news coverage about the company an impact score of 47.56 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days. How do I buy shares of Mesoblast? Shares of MEOBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mesoblast's stock price today? One share of MEOBF stock can currently be purchased for approximately $1.03. How big of a company is Mesoblast? Mesoblast has a market capitalization of $634.14 million. MarketBeat Community Rating for Mesoblast (OTCMKTS MEOBF)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 37 (Vote Outperform)Underperform Votes: 27 (Vote Underperform)Total Votes: 64MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MEOBF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEOBF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: Should I follow buy, hold and sell recommendations?